Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02390414 · ClinicalTrials.gov registry record
The Myelodysplasia Transplantation-Associated Outcomes (MDS-TAO) Study
A clinical trial, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- 290
- Enrollment target
NCT02390414: Completed study, sponsored by Dana-Farber Cancer Institute.
NCT02390414 is a clinical trial that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 290 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02390414 has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- 290 participants
- Enrollment target
Study Summary
The purpose of this observational study is to compare overall survival in older adults with myelodysplastic syndromes (MDS) who receive reduced intensity conditioning hematopoietic stem cell transplant (RIC HSCT) versus those who do not receive HSCT.
Primary Outcome
To prospectively compare the overall survival of patients in the HSCT group to that of patients in the non-HSCT group.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 290 participants |
| Start Date | 2011-05 |
| Est. Completion | 2020-09 |
What the finished NCT02390414 record still lists
NCT02390414 is an observational study that tracks outcomes without assigning an intervention. The registered 290 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02390414 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02390414 about?
NCT02390414 is a clinical study titled "The Myelodysplasia Transplantation-Associated Outcomes (MDS-TAO) Study". The purpose of this observational study is to compare overall survival in older adults with myelodysplastic syndromes (MDS) who receive reduced intensity conditioning hematopoietic stem cell transplant (RIC HSCT) versus those who do not receive HSCT.
What is the current status of trial NCT02390414?
This trial is currently completed. The enrollment target is 290 participants. The study started on 2011-05. Estimated completion is 2020-09.
Who is sponsoring clinical trial NCT02390414?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00775476 · 290 participants · Phase 2
Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine
- NCT01874197 · 290 participants · NA
Branched Thoracic Endovascular Grafts for the Treatment of Thoraco-abdominal Aortic
- NCT04331353 · 290 participants · NA
The Allergen Reduction and Child Health Study (ARCHS)
- NCT04649008 · 290 participants · Early Phase 1
Localizing Epileptic Networks Using MRI and iEEG
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia